Other

Estimated Fair Value

DexCom Estimated Fair Value increased by 20.0% to $1.30B in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionOther
CategoryLiquidity
SignalHigher is better
VolatilityVolatile
First reportedQ4 2023
Last reportedQ1 2026

How to read this metric

An increase relative to amortized cost indicates unrealized gains, while a decrease indicates unrealized losses due to market volatility or interest rate changes.

Detailed definition

The current market value of debt securities classified as available-for-sale, excluding accrued interest. This metric pr...

Peer comparison

Standard for insurers; peers with similar duration profiles will show similar sensitivity to market interest rate changes.

Metric ID: other_debt_securities_available_for_sale_excluding_accru_fbe99d

Historical Data

5 periods
 Q4 '24Q2 '25Q3 '25Q4 '25Q1 '26
Value$1.97B$1.77B$1.49B$1.08B$1.30B
QoQ Change-10.3%-16.0%-27.3%+20.0%
YoY Change-45.2%
Range$1.08B$1.97B
CAGR-34.3%
Avg YoY Growth-45.2%
Median YoY Growth-45.2%

Frequently Asked Questions

What is DexCom's estimated fair value?
DexCom (DXCM) reported estimated fair value of $1.30B in Q1 2026.
What does estimated fair value mean?
The current market price of the company's available-for-sale debt investments.